All In Biotech

Drug Trial Radar · NCT06889012

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1018" and Coadministration of "BR1018A" and "BR1018B" in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

May 7, 2025

Primary completion

Jul 23, 2025

Study completion Jul 23, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1018 and coadministration of BR1018A and BR1018B in healthy volunteers

Conditions

  • Essential Hypertension
  • Primary Hypercholesterolemia

Interventions

  • BR1018Drug

    One tablet administered alone

  • BR1018ADrug

    One tablet administered alone

  • BR1018BDrug

    One tablet administered alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCtTime frame: 0-72 hours after administration
  2. CmaxTime frame: 0-72 hours after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Center, H PLUS Yangji Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.